Primary resistance describes the inherent lack of ability to respond to PD-1 and PD-L1 inhibitors due to the tumor microenvironment, primarily through insufficient PD-1/PD-L1 expression, disruption of critical immune signaling pathways, or lower tumor mutational burden. The gene discussed is PDCD1; the disease is neoplasm.